Communiqués

09/07/24 Dr James Campbell appointed AusBiotech Chair AQ
17/04/23 Patrys secures US patents for antibody technology AQ
30/11/22 Patrys : Insights Care Magazine | Interview with Dr James Campbell PU
18/11/22 Patrys Appoints Global Biotechnology Leader as Chairman - In Preparation for First Clinical Trial for Groundbreaking Cancer Therapy BU
17/10/22 Patrys : INTERVIEW | Dr James Campbell on Proactive PU
28/07/22 Patrys : Appendix 4C - Quarterly - 30 June 2022 PU
28/04/22 Patrys : Appendix 4C - Quarterly - 31 March 2022 PU
14/04/22 Patrys : Application for quotation of securities - PAB PU
23/03/22 New research: Scientists determine structure of a DNA damage ‘First Responder’ protein PU
24/02/22 Patrys : Appendix 4D - Half Year Accounts - 31 December 2021 PU
08/02/22 Patrys : Application for quotation of securities - PAB PU
07/02/22 Patrys : ADC Deals Making Headlines PU
31/01/22 Patrys : Appendix 4C - Quarterly - 31 December 2021 PU
09/12/21 Patrys : Ceasing to be a substantial holder from MQG PU
07/12/21 Patrys : Application for quotation of securities - PAB PU
06/12/21 Patrys : Change of Director's Interest Notices x2 PU
05/12/21 Patrys : Application for quotation of securities - PAB PU
23/11/21 Patrys : Notification regarding unquoted securities - PAB PU
18/11/21 Patrys : Notification regarding unquoted securities - PAB PU
11/11/21 Becoming a substantial holder from MQG PU
09/11/21 Rights Issue Offer Document PU
16/06/21 Patrys Limited : Announces Publication of PAT-DX1 Preclinical Data in JCI - Insight BU
28/09/20 Patrys : Adds Full Human Antibody to Deoxymab Portfolio PU
28/09/20 Patrys : Adds Full Human Antibody to Deoxymab Portfolio PU
03/08/20 Patrys : Entitlement Offer Results and Shortfall Notification PU
Aucun résultat pour cette recherche